Ｍｅｒｃｋ＆Ｃｏ公司的双膦酸盐阿仑膦酸（ａｌｅｎｄｒｏｎａｔｅ，Ｆｏｓａｍａｘ）一周用１次的制剂在其欧盟的第一个市场英国上市，用以预防绝经后骨质疏松症。继后，公司将争取在更多的欧盟国家获得批准。 ７０ｍｇ一周用１次的 Ｆｏｓａｍａｘ新制剂的 ４周包装定价为３ Merck & Co.’s bisphosphonate alendronate (fosamax), a once-a-week formulation, is marketed in the UK’s first market in the UK to prevent postmenopausal osteoporosis. Following that, the company will seek approval in more EU countries. A 4 week package of 70 mg once weekly Fosamax formulation is priced at 3